Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies

Authors: Valentina Rapozzi, Sonia Zorzet, Marina Zacchigna, Emilia Della Pietra, Susanna Cogoi, Luigi E Xodo

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Porphyrin TMPyP4 (P4) and its C14H28-alkyl derivative (C14) are G-quadruplex binders and singlet oxygen (1O2) generators. In contrast, TMPyP2 (P2) produces 1O2 but it is not a G-quadruplex binder. As their photosensitizing activity is currently undefined, we report in this study their efficacy against a melanoma skin tumour and describe an in vitro mechanistic study which gives insights into their anticancer activity.

Methods

Uptake and antiproliferative activity of photoactivated P2, P4 and C14 have been investigated in murine melanoma B78-H1 cells by FACS, clonogenic and migration assays. Apoptosis was investigated by PARP-1 cleavage and annexin-propidium iodide assays. Biodistribution and in vivo anticancer activity were tested in melanoma tumour-bearing mice. Porphyrin binding and photocleavage of G-rich mRNA regions were investigated by electrophoresis and RT-PCR. Porphyrin effect on ERK pathway was explored by Western blots.

Results

Thanks to its higher lipophylicity C14 was taken up by murine melanoma B78-H1 cells up to 30-fold more efficiently than P4. When photoactivated (7.2 J/cm2) in B78-H1 melanoma cells, P4 and C14, but not control P2, caused a strong inhibition of metabolic activity, clonogenic growth and cell migration. Biodistribution studies on melanoma tumour-bearing mice showed that P4 and C14 localize in the tumour. Upon irradiation (660 nm, 193 J/cm2), P4 and C14 retarded tumour growth and increased the median survival time of the treated mice by ~50% (P <0.01 by ANOVA), whereas porphyrin P2 did not. The light-dependent mechanism mediated by P4 and C14 is likely due to the binding to and photocleavage of G-rich quadruplex-forming sequences within the 5′-untranslated regions of the mitogenic ras genes. This causes a decrease of RAS protein and inhibition of downstream ERK pathway, which stimulates proliferation. Annexin V/propidium iodide and PARP-1 cleavage assays showed that the porphyrins arrested tumour growth by apoptosis and necrosis. C14 also showed an intrinsic light-independent anticancer activity, as recently reported for G4-RNA binders.

Conclusions

Porphyrins P4 and C14 impair the clonogenic growth and migration of B78-H1 melanoma cells and inhibit melanoma tumour growth in vivo. Evidence is provided that C14 acts through light-dependent (mRNA photocleavage) and light-independent (translation inhibition) mechanisms.
Appendix
Available only for authorised users
Literature
1.
Dolmans DE, Fukumura D, Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer. 2003, 3: 380-387. 10.1038/nrc1071CrossRefPubMed
2.
3.
Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q: Photodynamic therapy. J Natl Cancer Inst. 1998, 90: 889-905. 10.1093/jnci/90.12.889PubMedCentralCrossRefPubMed
4.
Miller JB: Photodynamic therapy: the sensitization of cancer cells to light. J Chem Educ. 1999, 76: 592-594. 10.1021/ed076p592.CrossRef
5.
Pervaiz S: Reactive oxygen-dependent production of novel photochemotherapeutic agents. FASEB J. 2001, 15: 612-617. 10.1096/fj.00-0555revCrossRefPubMed
6.
Josefsen LB, Boyle RW: Photodynamic therapy and the development of metal-based photosensitizers. Metal-Based Drugs. 2008, 2008: 1-24.CrossRef
7.
Castano AP, Demidova TN, Hamblin MR: Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn Photodyn Ther. 2004, 1: 279-293. 10.1016/S1572-1000(05)00007-4.CrossRef
8.
Castano AP, Demidova TN, Hamblin MR: Mechanisms in photodynamic therapy: part three-photosensitizers pharmacokinetics, biodistribution, tumour localization and modes of tumour destruction. Photodiagn Photodyn Ther. 2005, 2: 91-106. 10.1016/S1572-1000(05)00060-8.CrossRef
9.
Comuzzi C, Cogoi S, Overhand M, Van der Marel GA, Overkleeft HS, Xodo LE: Synthesis and biological evaluation of new pentaphyrin macrocycles for photodynamic therapy. J Med Chem. 2006, 49: 196-204. 10.1021/jm050831lCrossRefPubMed
10.
Ballico M, Rapozzi V, Xodo LE, Comuzzi C: Metallation of pentaphyrin with Lu[III] dramatically increases reactive-oxygen species production and cell phototoxicity. Eur J Med Chem. 2011, 46: 712-720. 10.1016/j.ejmech.2010.12.007CrossRefPubMed
11.
Rapozzi V, Beverina L, Salice P, Pagani GA, Camerin M, Xodo LE: Photooxidation and phototoxicity of pi-extended squaraines. J Med Chem. 2010, 53: 2188-2196. 10.1021/jm901727jCrossRefPubMed
12.
Rapozzi V, Zacchigna M, Biffi S, Garrovo C, Cateni F, Stebel M, Zorzet S, Bonora GM, Drioli S, Xodo LE: Conjugated PDT drug: photosensitizing activity and tissue distribution of PEGylated pheophorbide a. Cancer Biol Ther. 2010, 10: 471-482. 10.4161/cbt.10.5.12536CrossRefPubMed
13.
Rapozzi V, Miculan M, Xodo LE: Evidence that photoactivated pheophorbide a causes in human cancer cells a photodynamic effect involving lipid peroxidation. Cancer Biol Ther. 2009, 8: 1318-1327. 10.4161/cbt.8.14.8628CrossRefPubMed
14.
Rapozzi V, Zorzet S, Zacchigna M, Drioli S, Xodo LE: The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice. Invest New Drugs. 2013, 31: 192-199. 10.1007/s10637-012-9844-4CrossRefPubMed
15.
Xodo LE, Rapozzi V, Zacchigna M, Drioli S, Zorzet S: The chlorophyll catabolite pheophorbide a as a photosensitizer for the photodynamic therapy. Curr Med Chem. 2012, 19: 799-807. 10.2174/092986712799034879CrossRefPubMed
16.
Senge MO, Brandt JC: Temoporfin Foscan®, 5, 10, 15, 20-tetra[m-hydroxyphenyl]chlorin]-a second-generation photosensitizer. Photochem Photobiol. 2011, 87: 1240-1246. 10.1111/j.1751-1097.2011.00986.xCrossRefPubMed
17.
Chan WM, Lim TH, Pece A, Silva R, Yoshimura N: Verteporfin PDT for non-standard indications-a review of current literature. Graefes Arch Clin Exp Ophthalmol. 2010, 248: 613-626. 10.1007/s00417-010-1307-zCrossRefPubMed
18.
Hurley LH, Von Hoff DD, Siddiqui-Jain A, Yang D: Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol. 2006, 33: 498-512. 10.1053/j.seminoncol.2006.04.012CrossRefPubMed
19.
Han H, Langley DR, Rangan A, Hurley LH: Selective interactions of cationic porphyrins with G-quadruplex structures. J Am Chem Soc. 2001, 123: 8902-8913. 10.1021/ja002179jCrossRefPubMed
20.
Mikami-Terao Y, Akiyama M, Yuza Y, Yanagisawa T, Yamada O, Yamada H: Antitumour activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. Cancer Lett. 2008, 261: 226-234. 10.1016/j.canlet.2007.11.017CrossRefPubMed
21.
Morris MJ, Wingate KL, Silwal J, Leeper TC, Basu S: The porphyrin TmPyP4 unfolds the extremely stable G-quadruplex in MT3-MMP mRNA and alleviates its repressive effect to enhance translation in eukaryotic cells. Nucleic Acids Res. 2012, 40: 4137-4145. 10.1093/nar/gkr1308PubMedCentralCrossRefPubMed
22.
Parkinson GN, Lee MP, Neidle S: Crystal structure of parallel quadruplexes from human telomeric DNA. Nature. 2002, 417: 876-880. 10.1038/nature755CrossRefPubMed
23.
Huppert JL, Bugaut A, Kumari S, Balasubramanian S: G-quadruplexes: the beginning and end of UTRs. Nucleic Acids Res. 2008, 36: 6260-6268. 10.1093/nar/gkn511PubMedCentralCrossRefPubMed
24.
Kumari S, Bugaut A, Huppert JL, Balasubramanian S: An RNA G-quadruplex in the 5′ UTR of the NRAS proto-oncogene modulates translation. Nat Chem Biol. 2007, 3: 218-221. 10.1038/nchembio864PubMedCentralCrossRefPubMed
25.
Bugaut A, Balasubramanian S: 5′-UTR RNA G-quadruplexes: translation regulation and targeting. Nucleic Acids Res. 2012, 40: 4727-4741. 10.1093/nar/gks068PubMedCentralCrossRefPubMed
26.
Lammich S, Kamp F, Wagner J, Nuscher B, Zilow S, Ludwig AK, Willem M, Haass C: Translational repression of the disintegrin and metalloprotease ADAM10 by a stable G-quadruplex secondary structure in its 5′-untranslated region. J Biol Chem. 2011, 286: 45063-45072. 10.1074/jbc.M111.296921PubMedCentralCrossRefPubMed
27.
Weng HY, Huang HL, Zhao PP, Zhou H, Qu LH: Translational repression of cyclin D3 by a stable G-quadruplex in its 5′ UTR: implications for cell cycle regulation. RNA Biol. 2012, 9: 1099-1100. 10.4161/rna.21210PubMedCentralCrossRefPubMed
28.
Bugaut A, Rodriguez R, Kumari S, Hsu ST, Balasubramanian S: Small molecule-mediated inhibition of translation by targeting a native RNA G-quadruplex. Org Biomol Chem. 2010, 8: 2771-2776. 10.1039/c002418jPubMedCentralCrossRefPubMed
29.
Santarpia L, Lippman SM, El-Naggar AK: Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012, 16: 103-119. 10.1517/14728222.2011.645805PubMedCentralCrossRefPubMed
30.
Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004, 4: 937-947. 10.1038/nrc1503CrossRefPubMed
31.
Faudale M, Cogoi S, Xodo LE: Photoactivated cationic alkyl-substituted porphyrin binding to g4-RNA in the 5′-UTR of KRAS oncogene represses translation. Chem Commun (Camb). 2012, 48: 874-876. 10.1039/c1cc15850cCrossRef
32.
Ye Y, Wang H, Chu JH, Chou GX, Yu ZL: Activation of p38 MAPK pathway contributes to the melanogenic property of apigenin in B16 cells. Exp Dermatol. 2011, 20: 755-757. 10.1111/j.1600-0625.2011.01297.xCrossRefPubMed
33.
Gross E, Ehrenberg B, Johnson FM: Singlet oxygen generation by porphyrins and the kinetics of 9, 10-dimethylanthracene photosensitization in liposomes. Photochem Photobiol. 1993, 57: 808-813. 10.1111/j.1751-1097.1993.tb09215.xCrossRefPubMed
34.
Reddi E, Ceccon M, Valduga G, Jori G, Bommer JC, Elisei F, Latterini L, Mazzucato U: Photophysical properties and antibacterial activity of meso-substituted cationic porphyrins. Photochem Photobiol. 2002, 75: 462-470. 10.1562/0031-8655(2002)075<0462:PPAAAO>2.0.CO;2CrossRefPubMed
35.
Ricchelli F, Franchi L, Miotto G, Borsetto L, Gobbo S, Nikolov P, Bommer JC, Reddi E: Meso-substituted tetra-cationic porphyrins photosensitize the death of human fibrosarcoma cells via lysosomal cells via lysosomal targeting. Int J Biochem Cell Biol. 2005, 37: 306-319. 10.1016/j.biocel.2004.06.013CrossRefPubMed
36.
O’Brien MA, Moravec RA, Riss TL: Poly (ADP-ribose) polymerase cleavage monitored in situ in apoptotic cells. Biotechniques. 2001, 30: 886-891.PubMed
37.
Villanueva A, Jori G: Pharmacokinetic and tumour-photosensitizing properties of the cationic porphyrinmeso-tetra(4 N-methylpyridyl)porphine. Cancer Lett. 1993, 73: 59-64. 10.1016/0304-3835(93)90188-FCrossRefPubMed
38.
Jori G: Photodynamic therapy: basic and preclinical aspects. Organic Photochemistry and photobiology. Edited by: Horspool W. 2004, 146-1-10-Boca Raton, FL: CRC Press
39.
Villanueva A, Caggiari L, Jori G, Milanesi C: Morphological aspects of an experimental tumour photosensitized with a meso-substituted cationic porphyrin. J Photochem Photobiol B. 1994, 23: 49-56. 10.1016/1011-1344(93)06982-9CrossRefPubMed
40.
Eddy J, Maizels N: Gene function correlates with potential for G4 DNA formation in the human genome. Nucleic Acids Res. 2006, 34: 3887-3896. 10.1093/nar/gkl529PubMedCentralCrossRefPubMed
41.
Biffi G, Tannahill D, McCafferty J, Balasubramanian S: Quantitative visualization of DNA G-quadruplex structures in human cells. Nat Chem. 2013, 5: 182-186. 10.1038/nchem.1548PubMedCentralCrossRefPubMed
42.
Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH: Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci USA. 2002, 99: 11593-11598. 10.1073/pnas.182256799PubMedCentralCrossRefPubMed
43.
McLuckie KI, Waller ZA, Sanders DA, Alves D, Rodriguez R, Dash J, McKenzie GJ, Venkitaraman AR, Balasubramanian S: G-quadruplex-binding benzo[a]phenoxazines down-regulate c-KIT expression in human gastric carcinoma cells. J Am Chem Soc. 2011, 133: 2658-2663. 10.1021/ja109474cPubMedCentralCrossRefPubMed
44.
Cogoi S, Xodo LE: G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res. 2006, 34: 2536-2549. 10.1093/nar/gkl286PubMedCentralCrossRefPubMed
45.
Cogoi S, Paramasivam M, Spolaore B, Xodo LE: Structural polymorphism within a regulatory element of the human KRAS promoter: formation of G4-DNA recognized by nuclear proteins. Nucleic Acids Res. 2008, 36: 3765-3780. 10.1093/nar/gkn120PubMedCentralCrossRefPubMed
46.
Cogoi S, Paramasivam M, Membrino A, Yokoyama KK, Xodo LE: The KRAS promoter responds to Myc-associated zinc finger and poly(ADP-ribose)polymerase 1 proteins, which recognize a critical quadruplex-forming G4-element. J Biol Chem. 2010, 285: 22003-22016. 10.1074/jbc.M110.101923PubMedCentralCrossRefPubMed
47.
Membrino A, Cogoi S, Pedersen EB, Xodo LE: G4-DNA formation in the HRAS promoter and rational design of decoy oligonucleotides for cancer therapy. PLoS One. 2011, 6: 1-15.CrossRef
48.
Oba J, Nakahara T, Abe T, Hagihara A, Moroi Y, Furue M: Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. J Dermatol Sci. 2011, 62: 116-123. 10.1016/j.jdermsci.2011.02.011CrossRefPubMed
49.
50.
51.
Paramasivan S, Rujan I, Bolton PH: Circular dichroism of quadruplex DNAs: applications to structure, cation effects and ligand binding. Methods. 2007, 43: 324-331. 10.1016/j.ymeth.2007.02.009CrossRefPubMed
52.
Gomez D, Guedin A, Mergny JL, Salles B, Riou JF, Teulade-Fichou MP, Calsou P: A G-quadruplex structure within the 5′-UTR of TRF-2 mRNA represses translation in human cells. Nucleic Acids Res. 2010, 38: 7187-7198. 10.1093/nar/gkq563PubMedCentralCrossRefPubMed
53.
Halder K, Largy E, Benzler M, Teulade-Fichou MP, Hartig JS: Efficient suppression of gene expression by targeting the 5′-UTR based RNA quadruplexes with bisquinolinum compounds. Chembiochem. 2011, 12: 1663-1668. 10.1002/cbic.201100228CrossRefPubMed
54.
Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, Thompson JF, Bron LP, Hersey P: Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol. 2005, 58: 1163-1169. 10.1136/jcp.2005.025957PubMedCentralCrossRefPubMed
55.
Cohen C, Zavala-Pompa A, Sequeira JH, Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron N, Arbiser JL: Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res. 2002, 8: 3728-3733.PubMed
56.
Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-354. 10.1038/nrc1609CrossRefPubMed
57.
Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS: Oncogeic Ha-Ras-induced signalling activates NF-kB transcriptional activity, which is required for cellular transformation. J Biol Chem. 1997, 272: 24113-24116. 10.1074/jbc.272.39.24113CrossRefPubMed
58.
Lin G, Tang Z, Ye Y-B, Chen Q: NF-kB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IkBa pathway. Oncology Rep. 2012, 27: 1727-1734.
59.
Rapozzi V, Umezawa K, Xodo LE: Role of NF-κB/Snail/RKIP loop in the response of tumour cells to photodynamic therapy. Lasers Surg Med. 2011, 43: 575-585.CrossRefPubMed
60.
61.
Matsuda K, Idezawa T, You XJ, Kothari NH, Fan H, Korc M: Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res. 2002, 62: 5611-5617.PubMed
62.
Vogt A: Advances in two-dimensional cell migration assay technologies. Eur Pharm Rev. 2010, 5: 26-29.
Metadata
Title
Anticancer activity of cationic porphyrins in melanoma tumour-bearing mice and mechanistic in vitro studies
Authors
Valentina Rapozzi
Sonia Zorzet
Marina Zacchigna
Emilia Della Pietra
Susanna Cogoi
Luigi E Xodo
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-75

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Function of RasGRP3 in the formation and progression of human breast cancer

Research

Conjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancer

Research

The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis

Research

Identification and validation of PROM1 and CRTC2 mutations in lung cancer patients

Research

DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells

Research

Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits